ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments
NCT06429059 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2025-09-26
Summary
GenieUs developed an analysis platform that will be tested to separate study participants with ALS into four categories based on blood work. These general categories are neuroinflammation, oxidative stress, impaired autophagy \& axonal transport, and mitochondrial dysfunction. Once a disease category is established, participants in this study will receive one of four individualized supplements for 6 months and we will determine whether these are slowing ALS progression: Astaxanthin will be given for the category of neuroinflammation, Protandim for oxidative stress, Melatonin for impaired autophagy and MitoQ for mitochondrial dysfunction. During the first 3 months, participants will have routine monitoring and in months 3 through 9 they will receive the assigned supplement.
Conditions
- Amyotrophic Lateral Sclerosis ALS
Interventions
- DRUG
-
Astaxanthin
Astaxanthin is a red-orange natural pigment belonging to a group of carotenoids called xanthophylls. In nature, astaxanthin is synthesized by microalgae and phytoplankton and biomagnifies in higher marine animals through the food chain. Natural astaxanthin is available as capsules, soft gels, tablets, powders, biomass, creams, energy drinks, oils and extracts and often contains other carotenoids. The compound is available as a United States Pharmacopeia (USP) verified supplement which ensures federally recognized standards for quality and purity (https://www.quality-supplements.org/verified-products/verified-products-listings).
- DRUG
-
Protandim
Protandim is an oral tablet derived from five different plants: Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), Curcuma longa (turmeric) and Bacopa monniera.
- DRUG
-
Melatonin
Melatonin is a hormone that has long been known to play a role in regulating sleep. Melatonin supplements are commonly used to treat insomnia, but in recent years, melatonin has been found to play a wider role in human physiology including the potential regulation of autophagy.
- DRUG
-
MitoQ
The active ingredient in MitoQ is ubiquinone, the same as found in coenzyme Q10 and idebenone. However, the ubiquinone in MitoQ is attached to a positively charged, lipophilic molecule called TPP (triphenyl phosphonium), which allows it to selectively accumulate in mitochondria. This makes it more potent than untargeted ubiquinone analogs at protecting mitochondria in cultured cells. It can be administered orally and, at least in animals, can cross the blood brain barrier and accumulate in brain mitochondria.
Sponsors & Collaborators
-
Temple University
collaborator OTHER - lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-06-12
- Primary Completion
- 2025-05-22
- Completion
- 2025-06-24
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
NCT04011748 ·Status: UNKNOWN ·Phase: PHASE2
-
Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata
NCT00484679 ·Status: COMPLETED ·Phase: PHASE2
-
Minoxidil Response Testing in Males With Androgenetic Alopecia
NCT02198261 ·Status: COMPLETED
-
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
NCT07226531 ·Status: ACTIVE_NOT_RECRUITING
-
Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)
NCT02676310 ·Status: TERMINATED ·Phase: PHASE1
-
Long-Term PF-06651600 for the Treatment of Alopecia Areata
NCT04006457 ·Status: COMPLETED ·Phase: PHASE3
-
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
NCT03759340 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment
NCT02591355 ·Status: COMPLETED ·Phase: NA
-
Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia
NCT02848300 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss
NCT01325350 ·Status: COMPLETED ·Phase: PHASE2
-
Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women
NCT00418249 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata
NCT00063076 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Computer-Assisted Hair Restoration Study Using ARTAS System
NCT05938569 ·Status: RECRUITING ·Phase: NA
-
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
NCT05244980 ·Status: COMPLETED ·Phase: PHASE1
-
Stem Cell Educator Therapy in Alopecia Areata
NCT01673789 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Topical Bimatoprost Effect on Androgen Dependent Hair Follicles
NCT02170662 ·Status: COMPLETED ·Phase: PHASE2
-
Intralesional Steroids in the Treatment of Alopecia Areata
NCT01898806 ·Status: TERMINATED ·Phase: PHASE4
-
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss
NCT04450589 ·Status: COMPLETED ·Phase: NA
-
Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata
NCT00187577 ·Status: COMPLETED ·Phase: NA
-
Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia
NCT03852992 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
NCT02503137 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia
NCT01286649 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects
NCT06045624 ·Status: WITHDRAWN ·Phase: PHASE1
-
Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study
NCT02914587 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)
NCT01451125 ·Status: COMPLETED ·Phase: PHASE2